Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 154 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR A Clinical Signal of Efficacy Observed with a Combination of Nivolumab... June 20, 2022 Olivia Newton-John Shares Positive News On Breast Cancer: “I’m Winning Over... January 28, 2020 Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... August 20, 2019 FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease July 19, 2021 Load more HOT NEWS ESMO Clinical Practice Guideline Express Update on the management of epithelial... Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... Reflections from our chief scientist: The rise of the whole organism For People with Cancer, Are Steroids the Best Treatment for Breathing...
